Oxidative
stress is one of the hallmarks of ischemic stroke. Catalase-based
(CAT) biomimetic complexes are emerging as promising therapeutic candidates
that are expected to act as neuroprotectants for ischemic stroke by
decreasing the damaging effects from H2O2. Unfortunately,
these molecules result in the unwanted production of the harmful hydroxyl
radical, HO•. Here, we report a series of salen-based
tri-manganese (Mn(III)) metallocryptands (1–3) that function as catalase biomimetics. These cage-like
molecules contain a unique “active site” with three
Mn centers in close proximity, an arrangement designed to facilitate
metal cooperativity for the effective dismutation of H2O2 with minimal HO• production. In fact,
significantly greater oxygen production is seen for 1–3 as compared to the monomeric Mn(Salen) complex, 1c. The most promising system, 1, was studied
in further detail and found to confer a greater therapeutic benefit
both in vitro and in vivo than the
monomeric control system, 1c, as evident from inter alia studies involving a rat model of ischemic stroke
damage and supporting histological analyses. We thus believe that
metallocryptand 1 and its analogues represent a new and
seemingly promising strategy for treating oxidative stress related
disorders.